ACNP - Italian Periodicals Catalogue

AAAAAA

ITA
ENG

Results: 1-17 |

Results: 17

A Multicenter Clinical Trial on the use of alpha(1)-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis

Authors: Lein, M Jung, K Hammerer, P Graefen, M Semjonow, A Stieber, P Ossendorf, M Luboldt, HJ Brux, B Stephan, C Schnorr, D Loening, SA

Citation: M. Lein et al., A Multicenter Clinical Trial on the use of alpha(1)-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis, PROSTATE, 47(2), 2001, pp. 77-84

Do modifications of nonequimolar assays for total prostate-specific antigen improve detection of prostate cancer?

Authors: Semjonow, A Oberpenning, F Weining, C Schon, M Brandt, B De Angelis, G Heinecke, A Hamm, M Stieber, P Hertle, L Schmid, HP

Citation: A. Semjonow et al., Do modifications of nonequimolar assays for total prostate-specific antigen improve detection of prostate cancer?, CLIN CHEM, 47(8), 2001, pp. 1472-1475

Cytogenetic analysis of multifocal bladder cancer supports a monoclonal origin and intraepithelial spread of tumor cells

Authors: Simon, R Eltze, E Schafer, KL Burger, H Semjonow, A Hertle, L Dockhorn-Dworniczak, B Terpe, HJ Bocker, W

Citation: R. Simon et al., Cytogenetic analysis of multifocal bladder cancer supports a monoclonal origin and intraepithelial spread of tumor cells, CANCER RES, 61(1), 2001, pp. 355-362

The clinical impact of different assays for prostate specific antigen

Authors: Semjonow, A De Angelis, G Oberpenning, F Schmid, HP Brandt, B Hertle, L

Citation: A. Semjonow et al., The clinical impact of different assays for prostate specific antigen, BJU INT, 86(5), 2000, pp. 590-597

Spectroscopic Imaging (H-1-2D-CSl) of the prostate: sequence optimization and correlation with histophatological results.

Authors: Stanka, M Eltze, E Semjonow, A Sievert, KD Maier, A Pfleiderer, B

Citation: M. Stanka et al., Spectroscopic Imaging (H-1-2D-CSl) of the prostate: sequence optimization and correlation with histophatological results., ROFO-F RONT, 172(7), 2000, pp. 623-629

Patterns of chromosomal imbalances in muscle invasive bladder cancer

Authors: Simon, R Burger, H Semjonow, A Hertle, L Terpe, HJ Bocker, W

Citation: R. Simon et al., Patterns of chromosomal imbalances in muscle invasive bladder cancer, INT J ONCOL, 17(5), 2000, pp. 1025-1029

Blood-borne cancer cells - Quo vadis?

Authors: Brandt, B Schmitt, H Feldner, JC Lelle, RJ Semjonow, A Beckmann, A

Citation: B. Brandt et al., Blood-borne cancer cells - Quo vadis?, INT J B MAR, 15(1), 2000, pp. 111-113

10 years of PSA - chemoprevention

Authors: Hammerer, P Semjonow, A

Citation: P. Hammerer et A. Semjonow, 10 years of PSA - chemoprevention, UROLOGE A, 39(4), 2000, pp. 302-303

From antigen to tumor marker. Clinical application of PSA research results

Authors: De Angelis, G Brandt, B Schmid, HP Semjonow, A

Citation: G. De Angelis et al., From antigen to tumor marker. Clinical application of PSA research results, UROLOGE A, 39(4), 2000, pp. 309-312

Radical prostatectomy: Survival outcome and correlation to prostate-specific antigen levels

Authors: Oberpenning, F Hamm, M Schmid, HP Hertle, L Semjonow, A

Citation: F. Oberpenning et al., Radical prostatectomy: Survival outcome and correlation to prostate-specific antigen levels, ANTICANC R, 20(6D), 2000, pp. 4969-4972

Prostate specific antigen in as a dynamic model in advanced prostate cancer

Authors: Schmid, HP Bernhard, JR Semjonow, A Hanselmann, S Hertle, L Maibach, R

Citation: Hp. Schmid et al., Prostate specific antigen in as a dynamic model in advanced prostate cancer, ANTICANC R, 20(6D), 2000, pp. 4985-4987

Neoadjuvant hormonal therapy in radical prostatectomy and radiation-treated patients

Authors: Schmid, HP Semjonow, A Aus, G Hertle, L

Citation: Hp. Schmid et al., Neoadjuvant hormonal therapy in radical prostatectomy and radiation-treated patients, UROL INTERN, 65(2), 2000, pp. 63-67

Prostate-specific antigen doubling time: A potential surrogate end point in hormone-refractory prostate cancer

Authors: Schmid, HP Semjonow, A Maibach, R

Citation: Hp. Schmid et al., Prostate-specific antigen doubling time: A potential surrogate end point in hormone-refractory prostate cancer, J CL ONCOL, 17(5), 1999, pp. 1645-1646

Guidelines of the DGU

Authors: Altwein, J Aumuller, G Berges, R Dreikorn, K Eickenberg, U Engelmann, U Gratzke, P Harzmann, R Haupt, G Hofner, K Jonas, D Jonas, U Krieg, M Muschter, R Pientka, L Ringert, R Schabel, J Schuldes, H Schweikert, U Semjonow, A Senge, T Tunn, U Tschuschke, C Vogel, J Weissbach, L Weisser, H Wirth, M Zwergel, T Zumbe, J

Citation: J. Altwein et al., Guidelines of the DGU, UROLOGE, 38(5), 1999, pp. 529-536

Guidelines of German urologists on the diagnosis of benign prostatic hyperplasia

Citation: J. Altwein et al., Guidelines of German urologists on the diagnosis of benign prostatic hyperplasia, UROLOGE, 38(3), 1999, pp. 297-303

The biologic lower detection limit of six ultrasensitive PSA assays

Authors: Junker, R Brandt, B Semjonow, A Erren, M Zechel, C Assmann, G

Citation: R. Junker et al., The biologic lower detection limit of six ultrasensitive PSA assays, ANTICANC R, 19(4A), 1999, pp. 2625-2628

Estradiol and high-dose dihydrotestosterone treatment causes changes in cynomolgus monkey prostate volume and histology identical to those caused by testosterone alone

Authors: Kamischke, A Weinbauer, GF Semjonow, A Lerchl, A Richter, KD Nieschlag, E

Citation: A. Kamischke et al., Estradiol and high-dose dihydrotestosterone treatment causes changes in cynomolgus monkey prostate volume and histology identical to those caused by testosterone alone, J ANDROLOGY, 20(5), 1999, pp. 601-610

Risultati: 1-17 |